Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$104.91
$103.67
$38.81
$104.98
$20.03B1.413.55 million shsN/A
Icon Plc stock logo
ICLR
Icon
$125.00
+0.7%
$108.25
$66.57
$211.00
$10.02B1.231.47 million shs1.12 million shs
Incyte Corporation stock logo
INCY
Incyte
$97.77
-2.1%
$95.55
$57.77
$112.29
$19.95B0.791.43 million shs1.02 million shs
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$428.71
+0.4%
$467.80
$284.48
$628.92
$12.19B1.19498,756 shs346,707 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.00%0.00%0.00%+1.68%+97.02%
Icon Plc stock logo
ICLR
Icon
+0.70%+5.64%+16.65%-16.99%-9.97%
Incyte Corporation stock logo
INCY
Incyte
-2.08%+2.62%+4.35%-9.80%+64.18%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
+0.45%+2.40%-15.69%-20.91%+43.04%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$104.91
$103.67
$38.81
$104.98
$20.03B1.413.55 million shsN/A
Icon Plc stock logo
ICLR
Icon
$125.00
+0.7%
$108.25
$66.57
$211.00
$10.02B1.231.47 million shs1.12 million shs
Incyte Corporation stock logo
INCY
Incyte
$97.77
-2.1%
$95.55
$57.77
$112.29
$19.95B0.791.43 million shs1.02 million shs
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$428.71
+0.4%
$467.80
$284.48
$628.92
$12.19B1.19498,756 shs346,707 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.00%0.00%0.00%+1.68%+97.02%
Icon Plc stock logo
ICLR
Icon
+0.70%+5.64%+16.65%-16.99%-9.97%
Incyte Corporation stock logo
INCY
Incyte
-2.08%+2.62%+4.35%-9.80%+64.18%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
+0.45%+2.40%-15.69%-20.91%+43.04%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
1.95
Reduce$92.13-12.19% Downside
Icon Plc stock logo
ICLR
Icon
2.27
Hold$149.3819.51% Upside
Incyte Corporation stock logo
INCY
Incyte
2.43
Hold$104.266.64% Upside
Medpace Holdings, Inc. stock logo
MEDP
Medpace
2.20
Hold$467.088.95% Upside

Current Analyst Ratings Breakdown

Latest MEDP, EXAS, ICLR, and INCY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
Icon Plc stock logo
ICLR
Icon
Set Price Target$125.00
5/4/2026
Incyte Corporation stock logo
INCY
Incyte
Reiterated RatingBuy$135.00
4/29/2026
Incyte Corporation stock logo
INCY
Incyte
Boost Price TargetMarket Perform$84.00 ➝ $90.00
4/29/2026
Incyte Corporation stock logo
INCY
Incyte
Boost Price TargetBuy$120.00 ➝ $123.00
4/24/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Lower Price TargetOutperform$522.00 ➝ $484.00
4/24/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Lower Price TargetEqual Weight$500.00 ➝ $450.00
4/24/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Lower Price TargetMarket Perform$460.00 ➝ $400.00
4/24/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
Lower Price TargetOutperform$565.00 ➝ $477.00
4/15/2026
Incyte Corporation stock logo
INCY
Incyte
Reiterated RatingBuy$135.00
4/6/2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
DowngradeBuy (B-)Hold (C+)
4/1/2026
Incyte Corporation stock logo
INCY
Incyte
UpgradeHold (C+)Buy (B-)
(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$3.25B6.17$1.27 per share82.83$12.58 per share8.34
Icon Plc stock logo
ICLR
Icon
$8.28B1.22$20.19 per share6.19$117.92 per share1.06
Incyte Corporation stock logo
INCY
Incyte
$5.14B3.80$6.05 per share16.16$28.15 per share3.47
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$2.53B4.84$17.09 per share25.08$20.95 per share20.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$207.95M-$1.10N/A209.822.02-6.40%0.53%0.22%N/A
Icon Plc stock logo
ICLR
Icon
$791.47M$7.3916.919.553.247.40%10.58%6.01%5/13/2026 (Estimated)
Incyte Corporation stock logo
INCY
Incyte
$1.29B$7.0813.8112.280.9426.71%26.66%19.77%N/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$451.12M$15.9126.9523.122.1617.19%120.89%24.79%7/20/2026 (Estimated)

Latest MEDP, EXAS, ICLR, and INCY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2026Q1 2026
Icon Plc stock logo
ICLR
Icon
$2.95$3.28+$0.33N/A$1.99 billion$2.00 billion
4/28/2026Q1 2026
Incyte Corporation stock logo
INCY
Incyte
$1.38$1.81+$0.43$1.47$1.22 billion$1.27 billion
4/22/2026Q1 2026
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$3.74$4.28+$0.54$4.28$697.82 million$706.60 million
2/13/2026Q4 2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$0.08-$0.21-$0.29-$0.45$860.59 million$878.38 million
2/10/2026Q4 2025
Incyte Corporation stock logo
INCY
Incyte
$1.96$1.80-$0.16$1.46$1.35 billion$1.51 billion
2/9/2026Q4 2025
Medpace Holdings, Inc. stock logo
MEDP
Medpace
$4.18$4.67+$0.49$4.67$689.53 million$708.45 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
N/AN/AN/AN/AN/A
Icon Plc stock logo
ICLR
Icon
N/AN/AN/AN/AN/A
Incyte Corporation stock logo
INCY
Incyte
N/AN/AN/AN/AN/A
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.97
2.43
2.17
Icon Plc stock logo
ICLR
Icon
0.31
1.06
1.06
Incyte Corporation stock logo
INCY
Incyte
0.01
3.68
3.60
Medpace Holdings, Inc. stock logo
MEDP
Medpace
N/A
0.85
0.85

Institutional Ownership

CompanyInstitutional Ownership
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
88.82%
Icon Plc stock logo
ICLR
Icon
95.61%
Incyte Corporation stock logo
INCY
Incyte
96.97%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
77.98%

Insider Ownership

CompanyInsider Ownership
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
1.20%
Icon Plc stock logo
ICLR
Icon
44.00%
Incyte Corporation stock logo
INCY
Incyte
17.80%
Medpace Holdings, Inc. stock logo
MEDP
Medpace
20.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
7,200190.89 million188.60 millionOptionable
Icon Plc stock logo
ICLR
Icon
41,90080.76 million45.22 millionOptionable
Incyte Corporation stock logo
INCY
Incyte
2,844199.78 million164.22 millionOptionable
Medpace Holdings, Inc. stock logo
MEDP
Medpace
6,20028.56 million22.71 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Exact Sciences stock logo

Exact Sciences NASDAQ:EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Icon stock logo

Icon NASDAQ:ICLR

$125.00 +0.87 (+0.70%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$124.83 -0.17 (-0.13%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Incyte stock logo

Incyte NASDAQ:INCY

$97.77 -2.08 (-2.08%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$97.78 +0.02 (+0.02%)
As of 04:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Medpace stock logo

Medpace NASDAQ:MEDP

$428.71 +1.92 (+0.45%)
Closing price 05/7/2026 04:00 PM Eastern
Extended Trading
$424.00 -4.71 (-1.10%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.